{"id":"ad26-zebov-batch-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This vaccine uses a non-replicating adenoviral vector to deliver the gene encoding the Ebola virus surface glycoprotein, triggering both cellular and humoral immune responses. The Ad26 vector is engineered to be safe and immunogenic while the expressed glycoprotein serves as the antigen target. This approach is part of a heterologous prime-boost vaccination strategy, often paired with MVA-EBOV as a booster dose.","oneSentence":"Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein, designed to elicit immune responses against Ebola virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:29.479Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ebola virus disease prevention"}]},"trialDetails":[{"nctId":"NCT02543268","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-09-21","conditions":"Healthy","enrollment":329}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ad26.ZEBOV-Batch #3","genericName":"Ad26.ZEBOV-Batch #3","companyName":"Crucell Holland BV","companyId":"crucell-holland-bv","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ad26.ZEBOV-Batch #3 is an intervention being studied in a clinical trial for its immunogenicity, safety, and tolerability in healthy adult participants. The mechanism of Ad26.ZEBOV-Batch #3 is unknown.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}